FTC Hytrin Order Clears Path For Four Generics; Cardizem CD Case Filed
Executive Summary
Geneva's settlement with the Federal Trade Commission regarding generic terazosin (Hytrin) could open up the market for up to four new entrants.
You may also be interested in...
Bristol Renounces Late-Listed Patents Under FTC Settlement
Bristol-Myers Squibb is surrendering its rights to a 30-month stay of approval in litigation over patents issued after an ANDA is on file at FDA
Bristol Renounces Late-Listed Patents Under FTC Settlement
Bristol-Myers Squibb is surrendering its rights to a 30-month stay of approval in litigation over patents issued after an ANDA is on file at FDA
K-Dur Case: Reverse Payments Not “Established” Antitrust Violations – Judge
Reverse payments from brand to generic companies in patent settlements are not "established" antitrust violations, an administrative law judge said in dismissing the Federal Trade Commission's antitrust case against Schering-Plough regarding K-Dur